Advanced or metastatic breast cancer. NHSE
commissioned. (Decision date - November 2020).
NICE TA816 - Alpelisib with fulvestrant for
treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced
breast cancer. (Decision date - September 2022).
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
